MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
Affected assets and topics
Article tone
Expected market reaction
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- free-analysis-rule-based-analysis
- Analysis version
- free-analysis-rule-based-analysis
- Article id
- 107589
- Timeframe
- 6h
Prediction lifecycle
-
Free Analysis Rule Based Analysis not AI NASDAQ Bullish 60%Generated 6h Excluded
Expired: not evaluated within 7 days of its 6h timeframe elapsing
Logged at publication, scored automatically once the window closes — never edited.
Original source
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS ; NCT 06743776) evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on July 15, 2026. Analysis and insights provided by AnalystMarkets AI.
This model on similar stories
Free Analysis Rule Based Analysis · 37.9% correct across 66 scored calls on indices See the full record